Literature DB >> 29261454

Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.

Dale Farkas1, Michael Hindle2, P Worth Longest1,2.   

Abstract

BACKGROUND: Inline dry powder inhalers (DPIs) are actuated by an external air source and have distinct advantages for delivering aerosols to infants and children, and to individuals with compromised lung function or who require ventilator support. However, current inline DPIs either perform poorly, are difficult to operate, and/or require large volumes (∼1 L) of air. The objective of this study was to develop and characterize a new inline DPI for aerosolizing spray-dried formulations with powder masses of 10 mg and higher using a dispersion air volume of 10 mL per actuation that is easy to load (capsule-based) and operate.
METHODS: Primary features of the new low air volume (LV) DPIs are fixed hollow capillaries that both pierce the capsule and provide a continuous flow path for air and aerosol passing through the device. Two different configurations were evaluated, which were a straight-through (ST) device, with the inlet and outlet capillaries on opposite ends of the capsule, and a single-sided (SS) device, with both the inlet and outlet capillaries on the same side of the capsule. The devices were operated with five actuations of a 10 mL air syringe using an albuterol sulfate (AS) excipient-enhanced growth (EEG) formulation. Device emptying and aerosol characteristics were evaluated for multiple device outlet configurations.
RESULTS: Each device had specific advantages. The best case ST device produced the smallest aerosol [mean mass median aerodynamic diameter (MMAD) = 1.57 μm; fine particle fraction <5 μm (FPF<5μm) = 95.2%)] but the mean emitted dose (ED) was 61.9%. The best case SS device improved ED (84.8%), but produced a larger aerosol (MMAD = 2.13 μm; FPF<5μm = 89.3%) that was marginally higher than the initial deaggregation target.
CONCLUSIONS: The new LV-DPIs produced an acceptable high-quality aerosol with only 10 mL of dispersion air per actuation and were easy to load and operate. This performance should enable application in high and low flow mechanical ventilation systems and high efficiency lung delivery to both infants and children.

Entities:  

Keywords:  active DPI; high efficiency DPI; inline DPI; nose-to-lung aerosol delivery; pediatric aerosol delivery

Mesh:

Substances:

Year:  2017        PMID: 29261454      PMCID: PMC6067687          DOI: 10.1089/jamp.2017.1424

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  30 in total

1.  Method to introduce mannitol powder to intubated patients to improve sputum clearance.

Authors:  Patricia Tang; Hak-Kim Chan; Dorrilyn Rajbhandari; Paul Phipps
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-10-20       Impact factor: 2.849

Review 2.  Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients.

Authors:  Rajiv Dhand
Journal:  Respir Care       Date:  2005-10       Impact factor: 2.258

3.  Aerosol Drug Delivery During Noninvasive Positive Pressure Ventilation: Effects of Intersubject Variability and Excipient Enhanced Growth.

Authors:  Ross L Walenga; P Worth Longest; Anubhav Kaviratna; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-01-11       Impact factor: 2.849

4.  A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates.

Authors:  G Pohlmann; P Iwatschenko; W Koch; H Windt; M Rast; M Gama de Abreu; F J H Taut; C De Muynck
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-02-19       Impact factor: 2.849

5.  Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.

Authors:  P Worth Longest; Laleh Golshahi; Srinivas R B Behara; Geng Tian; Dale R Farkas; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-05       Impact factor: 2.849

6.  Dry artificial lung surfactant and its effect on very premature babies.

Authors:  C J Morley; A D Bangham; N Miller; J A Davis
Journal:  Lancet       Date:  1981-01-10       Impact factor: 79.321

7.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.

Authors:  Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Ann Biomed Eng       Date:  2015-05-19       Impact factor: 3.934

8.  Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.

Authors:  Yoen-Ju Son; P Worth Longest; Michael Hindle
Journal:  Int J Pharm       Date:  2013-01-10       Impact factor: 5.875

9.  Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device.

Authors:  Michael Hindle; P Worth Longest
Journal:  J Pharm Pharmacol       Date:  2012-02-21       Impact factor: 3.765

Review 10.  Breathing easier: addressing the challenges of aerosolizing medications to infants and preschoolers.

Authors:  Jennifer L Goralski; Stephanie D Davis
Journal:  Respir Med       Date:  2014-06-25       Impact factor: 3.415

View more
  12 in total

1.  Use of Computational Fluid Dynamics (CFD) Dispersion Parameters in the Development of a New DPI Actuated with Low Air Volumes.

Authors:  Worth Longest; Dale Farkas; Karl Bass; Michael Hindle
Journal:  Pharm Res       Date:  2019-05-28       Impact factor: 4.200

Review 2.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

3.  Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.

Authors:  Dale Farkas; Michael Hindle; Serena Bonasera; Karl Bass; Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-08-29       Impact factor: 2.849

4.  Development of a New Inhaler for High-Efficiency Dispersion of Spray-Dried Powders Using Computational Fluid Dynamics (CFD) Modeling.

Authors:  Worth Longest; Dale Farkas
Journal:  AAPS J       Date:  2019-02-07       Impact factor: 4.009

5.  Near Elimination of In Vitro Predicted Extrathoracic Aerosol Deposition in Children Using a Spray-Dried Antibiotic Formulation and Pediatric Air-Jet DPI.

Authors:  Dale Farkas; Morgan L Thomas; Amr Hassan; Serena Bonasera; Michael Hindle; Worth Longest
Journal:  Pharm Res       Date:  2022-06-27       Impact factor: 4.200

6.  Computational Fluid Dynamics (CFD) Guided Spray Drying Recommendations for Improved Aerosol Performance of a Small-Particle Antibiotic Formulation.

Authors:  Worth Longest; Amr Hassan; Dale Farkas; Michael Hindle
Journal:  Pharm Res       Date:  2022-02-11       Impact factor: 4.200

7.  Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

8.  Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

9.  High-Efficiency Dry Powder Aerosol Delivery to Children: Review and Application of New Technologies.

Authors:  Karl Bass; Dale Farkas; Amr Hassan; Serena Bonasera; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2020-10-14       Impact factor: 3.433

10.  Initial Development of an Air-Jet Dry Powder Inhaler for Rapid Delivery of Pharmaceutical Aerosols to Infants.

Authors:  Connor Howe; Michael Hindle; Serena Bonasera; Vijaya Rani; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2020-08-04       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.